The U.S. government's recent procurement of additional ACAM2000® smallpox vaccine from Emergent BioSolutions underscores the enduring national priority of orthopoxvirus preparedness, according to GeoVax Labs, Inc. (Nasdaq: GOVX). The Atlanta-based clinical-stage biotechnology company noted that the award reinforces the importance of maintaining robust capabilities against smallpox and mpox threats, aligning with long-term objectives for the Strategic National Stockpile.
David Dodd, Chairman and Chief Executive Officer of GeoVax, stated that government procurement decisions are driven by long-term national preparedness rather than short-term outbreak cycles. He emphasized that continued federal investment validates the need for resilient manufacturing capacity, diversified vaccine supply, and regulatory readiness. GeoVax believes this environment strongly supports the accelerated development of its GEO-MVA vaccine candidate through an expedited regulatory pathway and the expansion of U.S.-based MVA vaccine manufacturing.
The announcement comes amid a global health security landscape marked by recurring mpox outbreaks, emerging high-consequence infectious diseases, and increased focus on domestic production of critical medical countermeasures. These trends reinforce the necessity of a resilient and diversified biodefense infrastructure capable of responding to both natural outbreaks and potential biological threats.
GeoVax's GEO-MVA program is a Modified Vaccinia Ankara (MVA)-based vaccine candidate being developed for protection against mpox and smallpox. Following positive scientific advice from the European Medicines Agency (EMA), GeoVax is pursuing an immunobridging strategy to an approved MVA vaccine, enabling a direct path into a registrational Phase 3 study without traditional Phase 1 or Phase 2 efficacy trials. The pivotal Phase 3 study is scheduled to initiate in the fourth quarter of 2026, with data readout of the immunobridging portion anticipated by mid-2027.
The program aims to expand domestic manufacturing capacity and strengthen orthopoxvirus vaccine supply resilience. GeoVax believes that continued federal emphasis on orthopox preparedness, combined with initiatives supporting domestic production of critical medical countermeasures, aligns well with the objectives of its GEO-MVA program and the broader goal of strengthening America's medical countermeasure infrastructure. For more information about GeoVax and its programs, visit www.geovax.com.
